Pfizer’s fourth-quarter results delivered a double beat on both revenues and earnings per share, helping to lift the Dow Jones Industrial Average by 0.8% on the following trading day. The company reported a 12% year-over-year increase in adjusted EPS, driven by stronger-than-expected performance in its oncology and biosimilars segments. Management also raised its full-year guidance for free cash flow to a range of $20 billion to $22 billion, underscoring robust cash generation as the company transitions away from pandemic-related vaccines.

Seeking to carve out market share in the burgeoning obesity drug space, Pfizer is advancing Metsera, a once-monthly GLP-1 therapy. The program is slated to include more than 20 pivotal studies in 2026, spanning combination regimens and special populations such as patients with type 2 diabetes. If approved, Metsera would become the first monthly injectable in its class, offering a differentiated dosing schedule compared with daily or weekly competitors and potentially improving patient adherence.

Topline data from the VESPER-3 Phase II trial revealed that Metsera achieved an average body-weight reduction of 14.5% at 24 weeks, closely matching the efficacy of Eli Lilly’s Zepbound and Novo Nordisk’s CagriSema in separate studies. Pfizer also reported favorable safety and tolerability profiles, with gastrointestinal events consistent with expectations for GLP-1 agents. These results have prompted Citi to maintain a neutral view on Novo Nordisk shares, highlighting the intensifying competitive landscape.

Trading at roughly 9 times forward earnings—well below the S&P 500 average multiple—Pfizer offers a 6.6% dividend yield, positioning the stock as a potential defensive play should market volatility increase. With over $30 billion in net liquidity and a pipeline expected to generate three to five new approvals annually through 2028, the company’s financial strength and attractive cash return policy may appeal to value-oriented and income-seeking investors.